Chemokines as mediators of neovascularization.
Chemokines as mediators of neovascularization.
复制标题
DOI：
10.1161/atvbaha.108.162925
复制
发表时间：
2008-11
期刊：
影响因子：
--
通讯作者：
Strieter RM
中科院分区：
文献类型：
--
作者：
Keeley EC;Mehrad B;Strieter RM
趋化因子是同源肝素结合蛋白的一个超家族，首次被描述为它们在招募白细胞到炎症部位的作用。趋化因子已被认为是在各种临床环境中，如恶性肿瘤、伤口修复、慢性纤维增生性疾病、心肌缺血和动脉粥样硬化中，介导生理性和病理性新生血管形成的关键因素。CXC趋化因子家族的成员，在结构上被定义为包含ELR氨基酸基序，是血管生成的有效诱导剂，而CXC趋化因子的另一个子集抑制血管生成。此外，一种CC趋化因子配体CCL2与动脉形成有关。在这篇文章中，我们回顾了目前关于趋化因子作为新血管形成介质的作用的文献。
Chemokines are a superfamily of homologous heparin-binding proteins, first described for their role in recruiting leukocytes to sites of inflammation. Chemokines have since been recognized as key factors mediating both physiologic and pathologic neovascularization in such diverse clinical settings as malignancy, wound repair, chronic fibroproliferative disorders, myocardial ischemia and atherosclerosis. Members of the CXC chemokine family, structurally defined as containing the ELR aminoacid motif, are potent inducers of angiogenesis, whereas another subset of the CXC chemokines inhibit angiogenesis. In addition, CCL2, a CC chemokine ligand, has been implicated in arteriogenesis. In this manuscript, we review the current literature on the role of chemokines as mediators of neovascularization.